RECOMBINATE 1000 IU

País: Israel

Idioma: inglés

Fuente: Ministry of Health

Ingredientes activos:

COAGULATION FACTOR VIII RECOMBINANT 1000 IU/VIAL

Disponible desde:

TEVA MEDICAL MARKETING LTD.

Código ATC:

B02BD02

formulario farmacéutico:

POWDER FOR SOLUTION FOR INJECTION

Vía de administración:

I.V

Fabricado por:

BAXTER S.A., BELGIUM

Grupo terapéutico:

COAGULATION FACTOR VIII

indicaciones terapéuticas:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

Fecha de autorización:

2010-07-01